Premium
Micro RNA 200a inhibits erythroid differentiation by targeting PDCD 4 and THRB
Author(s) -
Li Yanming,
Zhang Qian,
Du Zhenglin,
Lu ZhiChao,
Liu Shuge,
Zhang Lu,
Ding Nan,
Bao Binghao,
Yang Yadong,
Xiong Qian,
Wang Hai,
Zhang Zhaojun,
Qu Hongzhu,
Jia Haibo,
Fang Xiangdong
Publication year - 2017
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14377
Subject(s) - erythropoiesis , gata1 , rna , microrna , biology , transcriptome , microbiology and biotechnology , cellular differentiation , transcription factor , gene expression , gene , genetics , medicine , anemia
Summary Previous studies on erythropoiesis revealed that micro RNA s (mi RNA s) play a critical role in erythroid differentiation. Given the abundance of identified mi RNA s and the limited understanding of erythroid mi RNA s, additional examination is required. Here, two sets of erythroid differentiation mi RN ome data were analysed to screen for novel erythroid‐inhibiting mi RNA s. MIR 200A was selected based on its pattern of downregulated expression in the mi RN ome datasets during induction of erythroid differentiation. Overexpression of MIR 200A in K562 and TF ‐1 cells confirmed its inhibitory role in erythroid differentiation. Further in vivo study indicated that overexpression of mir200a inhibited primitive erythropoiesis of zebrafish. Transcriptome analyses after MIR200A overexpression in TF ‐1 cells indicated a significant role in regulating erythroid function and revealed potential regulation networks. Additionally, bioinformatics and experimental analyses confirmed that PDCD 4 (programmed cell death 4) and THRB (thyroid hormone receptor, beta) are both targets of MIR200A ‐3p. Gain‐ and loss‐of‐function studies of PDCD 4 and THRB revealed that the two targets were capable of promoting erythroid gene expression. Overall, our results revealed that microRNA 200a inhibits erythroid differentiation by targeting PDCD 4 and THRB .